Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LH 2007: PET-Adapted Strategy in Hodgkin Lymphoma
NCT00920153Phase 3Terminated
- Sponsor
- French Innovative Leukemia Organisation
- Start
- May 2008
- Primary completion
- Mar 2016
- Modality
- Nucleic Acid-Directed Small Molecules, Targeted Liposomes, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of vindesine, pegylated liposomal doxorubicin, carmustine, etoposide, methylprednisolone injection in Hodgkin lymphoma (HL), sponsored by French Innovative Leukemia Organisation. Started May 2008; status: terminated.
02
Drugs
vindesinepegylated liposomal doxorubicincarmustineetoposidemethylprednisolone injection
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00920153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00920153.